Testicular cancer is the most common cancer diagnosed among men ages 15-39 years, with a world-wide doubling in incidence over the past few decades. The five-year relative survival rate of men with testicular cancer is 95 percent. This success results in an average gain of about 40 years of life but also leads to the emergence of considerable and devastating morbidities. Given the young age at diagnosis (adolescence and young adulthood), the numerous sequelae of testicular cancer treatment have a substantially greater impact on morbidity and mortality than the disease itself.
These sequelae can include: ototoxicity, neurotoxicity, cardiovascular disease, hypertension, metabolic disease, renal insufficiency, hypogonadism, obesity, second malignant neoplasms, pulmonary fibrosis, infertility and psychosocial concerns. This is a highly curable disease, but to date, there are still a lot of unanswered questions regarding long-term effects of the most common treatment, platinum chemotherapy.
This study hopes to establish a means to better understand the long-term toxicities of ototoxicity and neurotoxicity, and in the future, develop interventions to help treat and prevent these toxicities from occurring in patients who receive cisplatin-based chemotherapy for germ cell tumors of the testis, extra-gonadal germ cell tumors or other types of cancer. In July 2020, The Platinum Study received funding from the National Cancer Institute in order to follow enrolled participants for at least another 5 years. Overall, it is planned to follow all men for life. During the next phase of the study, all participants will be asked to complete another questionnaire. For those patients initially enrolled at Memorial Sloan Kettering Cancer Center and Indiana University Melvin and Bren Simon Comprehensive Cancer Center, they may also be included in a group of approximately 200 people who will be invited to complete an in-person visits to collect more objective measures. If you have any questions or concerns as the study moves forward, please do not hesitate to contact us by phoning us at (833) 770-8700 or e-mailing us at firstname.lastname@example.org.
As noted above, this study is funded by the National Cancer Institute.